全文获取类型
收费全文 | 10590篇 |
免费 | 607篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 124篇 |
儿科学 | 287篇 |
妇产科学 | 201篇 |
基础医学 | 1129篇 |
口腔科学 | 286篇 |
临床医学 | 856篇 |
内科学 | 3272篇 |
皮肤病学 | 151篇 |
神经病学 | 960篇 |
特种医学 | 374篇 |
外科学 | 1682篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 389篇 |
眼科学 | 80篇 |
药学 | 610篇 |
中国医学 | 32篇 |
肿瘤学 | 866篇 |
出版年
2023年 | 153篇 |
2022年 | 263篇 |
2021年 | 554篇 |
2020年 | 328篇 |
2019年 | 391篇 |
2018年 | 431篇 |
2017年 | 315篇 |
2016年 | 371篇 |
2015年 | 385篇 |
2014年 | 538篇 |
2013年 | 567篇 |
2012年 | 831篇 |
2011年 | 771篇 |
2010年 | 420篇 |
2009年 | 406篇 |
2008年 | 606篇 |
2007年 | 567篇 |
2006年 | 549篇 |
2005年 | 454篇 |
2004年 | 381篇 |
2003年 | 327篇 |
2002年 | 287篇 |
2001年 | 150篇 |
2000年 | 168篇 |
1999年 | 138篇 |
1998年 | 58篇 |
1997年 | 36篇 |
1996年 | 37篇 |
1995年 | 33篇 |
1994年 | 38篇 |
1993年 | 24篇 |
1992年 | 63篇 |
1991年 | 59篇 |
1990年 | 60篇 |
1989年 | 53篇 |
1988年 | 62篇 |
1987年 | 51篇 |
1986年 | 43篇 |
1985年 | 50篇 |
1984年 | 34篇 |
1983年 | 19篇 |
1981年 | 14篇 |
1979年 | 25篇 |
1978年 | 17篇 |
1977年 | 13篇 |
1976年 | 13篇 |
1974年 | 21篇 |
1972年 | 17篇 |
1971年 | 16篇 |
1969年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Martino K Merrit S Boyakye K Sernas T Koller C Hauser CJ Lavery R Livingston DH 《The Journal of trauma》1999,46(3):369-71; discussion 372-3
102.
D'Andrea V Biancari F Catania A Di Matteo FM Sorrenti S Spyrou M Dibra A Foti N Ortensi A 《Il Giornale di chirurgia》1999,20(1-2):47-50
The Authors describe the interposition vein cuff technique as an adjuvant method to infrainguinal prosthetic bypass grafts. The haemodynamic, mechanical and humoral factors thought to be involved in the beneficial effects of the vein cuff are herein discussed. The results of the main series suggest the use of this method particularly in patients without any available autologous vein conduit requiring a below-knee popliteal or crural reconstruction. 相似文献
103.
Lucci S Mascagni D Rivolta R Arcieri S Candioli S Manigrasso A Papetti MT Cerutti L Torretta A Di Matteo FM Zaccagnino P 《Il Giornale di chirurgia》1999,20(11-12):461-469
The Authors, on the basis of their experience with neoplastic colorectal pathology and after a review of the Literature, report a reappraisal of the problems related to colorectal multiple carcinomas. They emphasize the importance of routine preoperative pancolonoscopy for the identification of possible synchronous tumors (both benign and malignant) and periodic endoscopic follow-up (ideally a life-long one) for the detection and removal of all adenomatous polyps as well as early stage metachronous carcinomas, especially for patients with HNPCC. Besides, they stress the importance of sensibilization of the population about the heritability of colorectal carcinomas. 相似文献
104.
Richard M. Smiley Eugene Ornstein Eugene J. Pantuck Carol B. Pantuck Richard S. Matteo 《Journal canadien d'anesthésie》1991,38(8):965-968
The metabolism of isoflurane and the investigational volatile anaesthetic desflurane to fluoride ion was examined in 25 surgical patients. The patients were randomly assigned to four groups, to receive isoflurane or desflurane at either 0.65 MAC or 1.25 MAC. Anaesthesia was induced in all patients with thiopentone and midazolam and included nitrous oxide 60% in addition to the volatile agent. Blood was drawn before induction and at the end of the operation for determination of serum fluoride ion concentration. Plasma fluoride ion concentrations increased (+ 1.36 +/- 0.93 microM, P less than 0.01) in patients receiving isoflurane but were unchanged (-0.13 +/- 0.50 microM) in patients receiving desflurane. Metabolic release of fluoride ion is less with desflurane than with isoflurane during administration of the anaesthetics to surgical patients, and is unlikely to be of clinical significance. 相似文献
105.
106.
107.
Grazia Arpino Stephanie J Green D Craig Allred Dannika Lew Silvana Martino C Kent Osborne Richard M Elledge 《Clinical cancer research》2004,10(17):5670-5676
PURPOSE: Preclinical data indicate that expression of the ErbB family of receptors, such as HER-2 and HER-1 (EGFR) may be involved in endocrine resistance. Evidence of resistance from clinical studies has been inconsistent. The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen. PATIENTS AND METHODS: Three hundred and forty nine patients had estrogen receptor (ER)-positive breast cancer and received daily tamoxifen as initial therapy for advanced disease. HER-2 gene amplification, detected by fluorescence in situ hybridization, and HER-1 expression, evaluated by immunohistochemistry, was determined on 136 and 204 patients, respectively. RESULTS: HER-2 amplification was correlated with lower ER (P = 0.02), HER-1 positivity (P = 0.004), and HER-2 protein overexpression (P < 0.00001). The response rate was 56% for HER-2 non-amplified versus 47% for HER-2 amplified tumors (P = 0.38), and 58% for HER-1-negative versus 36% for HER-1-positive (P = 0.05). Time to treatment failure (TTF) was 7 months for non-amplified HER-2 tumors and 5 months (P = 0.007) for amplified HER-2 tumors, and there was a trend toward a better overall survival (OS) in patients with non-amplified HER-2 tumors (median 31 versus 25 months, respectively, P = 0.07). For positive versus negative HER-1 tumors, TTF was 4 versus 8 months (P = 0.08) and median survival was 24 versus 31 months (P = 0.41). Combining HER-1 expression and HER-2 gene status, patients with both negative HER-1 expression and non-amplified HER-2 had longer TTF (P = 0.001) and OS (P = 0.03) than if either were positive. In multivariate analysis, HER-2 was not an independent factor for TTF and OS, although HER-1 was significant for TTF only (P = 0.001). CONCLUSION: Patients with HER-2 amplification and HER-1 expression had lower ER levels and were modestly less responsive to tamoxifen, suggesting that molecular events in addition to those involving the ErbB receptors are important in determining the endocrine-resistant phenotype. 相似文献
108.
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. 总被引:5,自引:0,他引:5
Hans Herbert Steiner Matteo Mario Bonsanto Philipp Beckhove Michael Brysch Karsten Geletneky Rezvan Ahmadi Rebecca Schuele-Freyer Paul Kremer Golamreza Ranaie Dejana Matejic Harald Bauer Marika Kiessling Stefan Kunze Volker Schirrmacher Christel Herold-Mende 《Journal of clinical oncology》2004,22(21):4272-4281
PURPOSE: Prognosis of patients with glioblastoma is poor. Therefore, in glioblastoma patients, we analyzed whether antitumor vaccination with a virus-modified autologous tumor cell vaccine is feasible and safe. Also, we determined the influence on progression-free survival and overall survival and on vaccination-induced antitumor reactivity. PATIENTS AND METHODS: In a nonrandomized study, 23 patients were vaccinated and compared with nonvaccinated controls (n = 87). Vaccine was prepared from patient's tumor cell cultures by infection of the cells with Newcastle Disease Virus, followed by gamma-irradiation, and applied up to eight times. Antitumor immune reactivity was determined in skin, blood, and relapsed tumor by delayed-type hypersensitivity skin reaction, ELISPOT assay, and immunohistochemistry, respectively. RESULTS: Establishment of tumor cell cultures was successful in approximately 90% of patients. After vaccination, we observed no severe side effects. The median progression-free survival of vaccinated patients was 40 weeks (v 26 weeks in controls; log-rank test, P = .024), and the median overall survival of vaccinated patients was 100 weeks (v 49 weeks in controls; log-rank test, P < .001). Forty-five percent of the controls survived 1 year, 11% survived 2 years, and there were no long-term survivors (> or = 3 years). Ninety-one percent of vaccinated patients survived 1 year, 39% survived 2 years, and 4% were long-term survivors. In the vaccinated group, immune monitoring revealed significant increases of delayed-type hypersensitivity reactivity, numbers of tumor-reactive memory T cells, and numbers of CD8(+) tumor-infiltrating T-lymphocytes in secondary tumors. CONCLUSION: Postoperative vaccination with virus-modified autologous tumor cells seems to be feasible and safe and to improve the prognosis of patients with glioblastomas. This could be substantiated by the observed antitumor immune response. 相似文献
109.
Donato Gemmati Alessia Ongaro Gian L Scapoli Matteo Della Porta Silvia Tognazzo Maria L Serino Eros Di Bona Francesco Rodeghiero Giuseppe Gilli Roberto Reverberi Angelo Caruso Michela Pasello Agnese Pellati Monica De Mattei 《Cancer epidemiology, biomarkers & prevention》2004,13(5):787-794
Folate and methionine metabolism is involved in DNA synthesis and methylation processes. Polymorphisms in the genes of folate metabolism enzymes have been associated with some forms of cancer. In a case-control study, we evaluated whether four common polymorphisms in methylenetetrahydrofolate reductase (MTHFR C677T and A1298C), methionine synthase (MS A2756G), and methionine synthase reductase (MTRR A66G) genes may have a role in altering susceptibility to adult acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). We analyzed DNA of 120 adult ALL, 200 NHL, and 257 healthy control subjects. Individual carrying the MTHFR 677TT genotype showed a 3.6-fold decreased ALL risk [odds ratio (OR) 0.28, 95% confidence interval (95% CI) 0.12-0.72] than wild-types. Similarly, MS 2756GG individuals showed a 5.0-fold decreased ALL risk (OR 0.20, 95% CI 0.02-1.45) than wild-types. In combined results, subjects with the MTHFR 677CT/TT and MS 2756AG/GG genotypes revealed a 3.6-fold ALL risk reduction (OR 0.28, 95% CI 0.14-0.58) and those with the MTHFR 677TT and MTRR 66AG genotypes revealed a 4.2-fold ALL risk reduction (OR 0.24, 95% CI 0.06-0.81). Finally, those with the MS 2756AG/GG and MTRR 66AG/GG genotypes revealed a 2.2-fold ALL risk reduction (OR 0.45, 95% CI 0.10-0.85). Single analysis for NHL did not show any significant difference for all the polymorphisms investigated, but in the low-grade NHL subgroup, we found a 2.0-fold risk reduction for the MTRR 66GG homozygous genotype (OR 0.50, 95% CI 0.25-0.99), which was higher (OR 0.37, 95% CI 0.14-0.85) when analyzed in combination with MS 2756AA genotype. These data are in accordance with the hypothesis that polymorphisms in the genes for folate and methionine metabolism might play a greater role in the occurrence of ALL than NHL by influencing DNA synthesis and/or DNA methylation. 相似文献
110.
Claire Joqueviel Véronique Gilard Robert Martino Myriam Malet-Martino Ulf Niemeyer 《Cancer chemotherapy and pharmacology》1997,40(5):391-399
Phosphorus-31 nuclear magnetic resonance spectroscopy was used to evaluate the stability of carboxycyclophosphamide (CXCP)
and carboxyifosfamide (CXIF) in human urine at pH 7.0 and 5.5 at 25°, 8°, −20°, and −80 °C. At 25 °C and pH 7.0, CXCP and
CXIF are relatively stable (≈10% degradation in 24 h). In contrast, they are much less stable at pH 5.5 (≈80% degradation
of CXIF and ≈50% degradation of CXCP in 24 h). The rate of degradation of CXCP and CXIF was a function of the storage temperature
of the urine samples but, even at −80 °C, was not negligible: ≈30% degradation for CXCP irrespective of pH and ≈40% and 50%
degradation for CXIF at pH 7.0 and 5.5, respectively, after storage for 6 months. CXCP was more stable than CXIF at either
pH (7.0 or 5.5) and at all storage temperatures (8°, −20°, or −80 °C) of the urine samples. CXCP and CXIF were more stable
at pH 7.0 than at pH 5.5, although this difference fell with decreasing temperatures to be almost negligible at −80 °C. To
ensure a true estimate of CXCP and CXIF levels, urine samples must be frozen and stored at −80 °C within a few hours of micturition.
CXCP and CXIF assays should also be carried out within 2 months and 1 month of storage, respectively.
Received: 13 July 1996 / Accepted: 20 January 1997 相似文献